IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

Results from the ELSPIRE study will be presented as late-breaking data at The Liver Meeting® 2026 and simultaneously published in AASLD’s flagship journal, HEPATOLOGY At Week 52, 85.3% of patients receiving IQIRVO® achieved normalization of ALP compared with 23.3% receiving placebo and was generally well tolerated Findings add to growing evidence supporting ALP normalization as an achievable treatment goal in PBC PARIS, FRANCE, 5 NOVEMBER 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data from the ELSPIRE Phase III study in people living with primary biliary cholangitis (PBC) and alkaline phosphatase (ALP) levels between 1- 1.67× upper limit…